Source: International Congress 2016 – Asthma management
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Isabelle Pouliquen (Uxbridge, United Kingdom), Isabelle Pouliquen, Daren Austin, Necdet Gunsoy, Steven Yancey. A weight-based exacerbation dose-response analysis of mepolizumab in severe asthma with eosinophilic phenotype. Eur Respir J 2016; 48: Suppl. 60, 4106

Member's Comments

No comment yet.

Related content which might interest you: Real-life treatment of severe eosinophilic asthma with mepolizumab Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Clinical response to mepolizumab in patients with severe eosinophilic asthma Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma Year: 2019 Cost-effectiveness of switching from omalizumab to mepolizumab in uncontrolled severe eosinophilic asthma Source: Virtual Congress 2020 – How do different treatment strategies translate into costs Year: 2020 Characterisation of exacerbations of severe eosinophilic asthma (SEA) on mepolizumab compared to placebo Source: International Congress 2017 – Asthma management Year: 2017 Mepolizumab in real-life treatment of severe eosinophilic asthma Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Mepolizumab and the response to oral prednisolone in patients with severe eosinophilic asthma Source: International Congress 2017 – Asthma management Year: 2017 Mepolizumab efficacy in patients with severe eosinophilic asthma and bronchiectasis Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019 Asthma exacerbations and eosinophilic inflammation 6 months after treatment with mepolizumab in refractory eosinophilic asthma Source: Annual Congress 2009 - Towards improving asthma control Year: 2009 Effects of omalizumab on markers of eosinophilic inflammation in patients with severe allergic asthma Source: Annual Congress 2011 - Biomarkers and exacerbations of asthma and COPD Year: 2011 Evaluation of therapeutic response to anti-IL5 treatment in severe eosinophilic asthma patients no responders to omalizumab Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019 Continued long-term mepolizumab in severe eosinophilic asthma protects from asthma worsening versus stopping mepolizumab: COMET trial Source: Virtual Congress 2020 – Recent innovations regarding the mechanisms and treatments of asthma Year: 2020 Differential treatment response to mepolizumab in severe eosinophilic asthma with nasal polyps Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Characterisation of severe eosinophilic asthma patients who failed Mepolizumab therapy Source: Virtual Congress 2020 – Monoclonal antibodies in asthma Year: 2020 Airway autoimmunity and response to a 14-day course of oral corticosteroids in patients with severe eosinophilic asthma Source: Virtual Congress 2020 – Clinical and laboratory pharmacology in asthma Year: 2020 Add-on omalizumab therapy reduces clinically significant and severe asthma exacerbations, and improves FEV1 in patients with severe persistent allergic asthma irrespective of age Source: Eur Respir J 2005; 26: Suppl. 49, 48s Year: 2005 Super-responder analysis and real-world one year effectiveness of benralizumab in severe eosinophilic asthma Source: Virtual Congress 2020 – Monoclonal antibodies; randomised controlled trials and real-world studies in asthma Year: 2020 A treatment regime based on induced sputum eosinophilia does not result in a reduction in exacerbations in refractory severe asthmatics Source: Annual Congress 2008 - Severe asthma: a heterogeneous clinical entity Year: 2008 Severe asthma exacerbations with eosinophilic bronchitis: a randomized controlled comparison of the anti-inflammatory effects of deflazacort vs. prednisone Source: Eur Respir J 2006; 28: Suppl. 50, 441s Year: 2006 Exacerbations of severe asthma in patients treated with mepolizumab Source: Eur Respir J, 52 (6) 1801127; 10.1183/13993003.01127-2018 Year: 2018 Stopping versus continuing long-term mepolizumab treatment in severe eosinophilic asthma (COMET study) Source: Eur Respir J, 59 (1) 2100396; 10.1183/13993003.00396-2021 Year: 2022